amifostine anhydrous has been researched along with fluorouracil in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gyergyay, F; Peters, GJ; Pinedo, HM; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA | 1 |
| Gyergyay, F; Peters, GJ; Smid, K; van der Wilt, CL; van Laar, JA | 1 |
| Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA | 1 |
| Rivoire, M | 1 |
| Byfield, JE | 1 |
| Bearman, SI; Jones, RB; Myers, S; Purdy, M; Shpall, EJ; Stemmer, SM | 1 |
| Fahlke, J; Lippert, H; Ridwelski, K | 1 |
| Altmann, S; Hoffmanns, H | 1 |
| Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K | 1 |
| Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E | 1 |
| Myerson, R | 1 |
| Birnbaum, E; Dietz, D; Fleshman, J; Kodner, I; Myerson, R; Picus, J; Ratkin, G; Zobeiri, I | 1 |
| Claussen, U; Dreidax, M; Dunst, J; Kuechler, A; Liehr, T; Pigorsch, SU; Wendt, TG | 1 |
| Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D | 1 |
| Chalian, AA; Hershock, D; Lustig, R; Machtay, M; Miller, L; Rosenthal, DI; Weber, RS; Weinstein, GS | 1 |
| Mazeron, JJ | 1 |
| Abdel-Wahab, M; Abitbol, A; Hamilton-Nelson, K; Harvey, M; Lewin, A; Markoe, A; Troner, M; Wu, J | 1 |
| Kaji, H; Maiguma, T; Makino, K; Teshima, D | 1 |
| Chloropoulou, PA; Giatromanolaki, A; Kouklakis, G; Koukourakis, MI; Lyratzopoulos, N; Manolas, K; Pitiakoudis, M; Sivridis, E; Tsoutsou, P | 1 |
| Alencar, NMN; Barbosa, CRN; Barbosa, SCM; Brito, GAC; Callado, RB; Carvalho, LL; Lima-Júnior, RCP; Lopes, CDH; Lucetti, LT; Pereira, VBM; Santana, APM; Silva, CAA; Wong, DVT | 1 |
1 review(s) available for amifostine anhydrous and fluorouracil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 trial(s) available for amifostine anhydrous and fluorouracil
| Article | Year |
|---|---|
New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
Topics: Amifostine; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Stem Cells | 1993 |
High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma.
Topics: Amifostine; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Mucous Membrane; Prospective Studies; Radiation-Protective Agents | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cytoprotection; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Mouth Mucosa; Postoperative Care; Preoperative Care; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Retrospective Studies; Stomatitis; Time Factors | 1999 |
Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Topics: Amifostine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Fluorouracil; Humans; Neoplasm Staging; Radiation Injuries; Radiation-Protective Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2000 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotection; Fluorouracil; Humans; Neoplasm Recurrence, Local; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Rectal Neoplasms | 2002 |
Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; DNA Damage; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Radiation-Protective Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2003 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel | 2005 |
Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiography; Rectal Neoplasms; Young Adult | 2011 |
16 other study(ies) available for amifostine anhydrous and fluorouracil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured | 1992 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Thrombocytopenia; Thymidylate Synthase; Time Factors; Weight Loss | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Random Allocation; Thrombocytopenia; Weight Loss | 1992 |
[Cancers of the colon and the rectum: news in 1992].
Topics: Amifostine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Levamisole; Rectal Neoplasms | 1992 |
Combined use of drugs and radiation in the treatment of liver metastases.
Topics: Amifostine; Bromodeoxyuridine; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms | 1986 |
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged | 2000 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Mastectomy, Modified Radical; Middle Aged; Nausea; Radiation Pneumonitis; Radiation-Protective Agents; Radiobiology; Radiodermatitis; Radiotherapy, Adjuvant; Survival Analysis; Vomiting | 2002 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Rectal Neoplasms | 2002 |
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Pilot Projects; Severity of Illness Index | 2003 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child; Cisplatin; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Radiation-Protective Agents; Radiotherapy Dosage; Survival Analysis | 2004 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Mastectomy; Methotrexate; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Protective Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors | 2005 |
Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.
Topics: Allopurinol; Amifostine; Antimetabolites, Antineoplastic; Calcium; Cell Line; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Fibroblasts; Fluorouracil; Free Radical Scavengers; Glutamine; Humans; Keratinocytes; Methotrexate; Periodontal Ligament; Protective Agents; Pyrazoles; Reactive Oxygen Species; Stomatitis | 2009 |
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protective Agents; Stomatitis; Xerostomia | 2019 |